|
| | XAMOTEROL HEMIFUMARATE Basic information |
| Product Name: | XAMOTEROL HEMIFUMARATE | | Synonyms: | XAMOTEROL FUMARATE;4-Morpholinecarboxamide, N-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-;XAMOTEROL HEMIFUMARATE USP/EP/BP;Xamoterolum;Ixazomib Impurity 63 | | CAS: | 81801-12-9 | | MF: | C16H25N3O5.C4H4O4 | | MW: | 455.461 | | EINECS: | | | Product Categories: | | | Mol File: | 81801-12-9.mol |  |
| | XAMOTEROL HEMIFUMARATE Chemical Properties |
| Melting point | 168-170°C | | solubility | H2O: 10 mg/mL at 60 °C, soluble | | form | solid | | color | white |
| | XAMOTEROL HEMIFUMARATE Usage And Synthesis |
| Originator | Sepan,Yamanouchi | | Uses | Xamoterol is an authentic β1-adrenoceptor (β1-AR) agonist that has been shown to mimic the autoantibody effect on rat atria β1-AR apoptosis. | | Uses | Stimulant (cardiac). | | Definition | ChEBI: Xamoterol is a member of morpholines. | | Manufacturing Process | A suspension of 1-p-benzyloxyphenoxy-2,3-epoxypropane (11.5 g) in
isopropanol (6 ml) is added to a stirred mixture of 4-(N-beta-
aminoethylcarbamoyl) morpholine hydrogen sulphate (12.7 g), potassium
hydroxide (7.0 g) and isopropanol (10 ml) and the mixture is stirred at 45°C
for 1 hour and then evaporated to dryness under reduced pressure. The
residual oil is stirred with water, the mixture is filtered and the solid residue is
dissolved in acetone. A 30% solution of hydrogen chloride in propanol is
added until the pH of the mixture is less than 2, and the mixture is filtered.
The solid residue is crystallised from water and there is thus obtained 1-p-
benzyloxyphenoxy-3-(beta-morpholinocarbonamidoethyl)amino-2-propanol
hydrochloride (4.9 g).
A solution of the above compound in a mixture of ethanol (20 ml) and acetic
acid (20 ml) is shaken with a 30% palladium-on-charcoal catalyst (0.1 g) in
an atmosphere of hydrogen at laboratory temperature and pressure until 250
ml of hydrogen is absorbed. The mixture is filtered, the filtrate is evaporated
to dryness under reduced pressure and to the residue is added a hot solution
of fumaric acid (1.25 g) in ethanol (15 ml). The mixture is kept at 5°C for 12
hours and is then filtered, and the solid residue is washed with hot ethanol
and then dried. There is thus obtained 1-p-hydroxyphenoxy-3-beta-
(morpholinocarbonamido)ethyl-amino-2-propanol hydrogen fumarate, m.p.
168-169°C (with decomposition).
The 4-(N-beta-aminoethylcarbamoyl)morpholine hydrogen sulphate used as
starting material may be obtained as follows:
Morpholine (4.35 g) and phenyl chloroformate (6.35 g) are separately and
simultaneously added dropwise during 20 min to a stirred mixture of toluene
(10 ml), water (5 ml) and sodium hydroxide (2 g) which is maintained at 0°C.
The mixture is stirred for a further 2 hours whilst the temperature is allowed
to rise to 20°C. The toluene solution is separated, the aqueous solution is extracted twice with toluene and the combined toluene solutions are washed
with water, dried and evaporated to dryness under reduced pressure. The
residue is crystallised from petroleum ether (boiling point 60-80°C) and there
is thus obtained N-phenoxycarbonylmorpholine, melting point 46.5-47.5°C.
A mixture of the above compound (11 g) and ethylenediamine (27.8 g) is
stirred at laboratory temperature for 3 days and the excess of ethylene
diamine is removed by evaporation under reduced pressure. The residue is
dissolved in methanol, the solution is cooled to 5°C and concentrated sulfuric
acid is added until the pH of the solution is 2. A filter-aid (Celite, 10 g) is
added and the mixture is stirred for 1 hour and then filtered. The filtrate is
evaporated to dryness under reduced pressure and the residue is stirred with
ethyl acetate. The mixture is filtered and there is thus obtained as solid
residue 4-(N-beta-aminoethylcarbamoyl)morpholine hydrogen sulphate,
melting point 168-169°C. | | Therapeutic Function | Beta-adrenergic blocker, Cardiac stimulant |
| | XAMOTEROL HEMIFUMARATE Preparation Products And Raw materials |
|
